ZURICH/BERLIN, Dec 14 (Reuters) - The Swiss blue-chip SMI (.SSMI) was seen opening 0.14% higher at 12,569 points on Tuesday, according to premarket indications by bank Julius Baer .
Here are some of the main factors that may affect Swiss stocks:
SWISS NATIONAL BANK
The Swiss National Bank's sight deposits rose by their highest amount in seven months last week, indicating policymakers are taking the first decisive steps to battle a rise in the value of the franc against its major rivals, particularly the euro. read more
A Paris appeals court on Monday slashed the penalty UBS must pay for allegedly helping wealthy clients in France evade taxes to 1.8 billion euros ($2 billion), but upheld that the Swiss bank was guilty of both promoting illegal banking services and money laundering. read more
Vifor Pharma AG
Australian biopharmaceutical giant CSL Ltd (CSL.AX) said it would buy Swiss drugmaker Vifor Pharma AG for $11.7 billion, aiming to diversify beyond the blood plasma collection business after taking a hit from COVID-19 curbs. read more
* Roche (ROG.S) said its Sars-Cov-2 antigen self test nasal was approved under health Canada's interim order. ROG.S
* Sika (SIKA.S) said it was opening a new technology centre and manufacturing plant in Pune, India for adhesives and sealants. SIKA.S
FORBO HOLDING AG (FORN.S): CREDIT SUISSE RAISES TARGET PRICE TO CHF 1825 FROM CHF 1730
LONZA GROUP AG (LONN.S): RBC RAISES TARGET PRICE TO CHF 720 FROM CHF 680
EMS CHEMIE HOLDING AG (EMSN.S): BERENBERG STARTS WITH BUY RATING AND PRICE TARGET OF CHF 1,100
SWISS LIFE HOLDING AG (SLHN.S): BERENBERG RAISES TARGET PRICE TO CHF 657 FROM CHF 546
NOVARTIS AG (NOVN.S): BERENBERG CUTS TARGET PRICE TO CHF 85 FROM CHF 88
Swiss November Producer/Import price index data due at 0730 GMT.
Our Standards: The Thomson Reuters Trust Principles.